The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Astellas Vows Intensive Investment in 6 Late-Stage Assets to Weather Patent Cliff: CEO
Astellas Pharma President and CEO Kenji Yasukawa on April 26 highlighted the company’s resolve to plow intensive resources into six late-stage pipelines, including the cancer drug candidate IMAB362 (zolbetuximab), in a bid to tackle a looming patent cliff for its…
To read the full story
Related Article
- Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
BUSINESS
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
- Aculys Rolls Out Spydia Nasal Spray in Japan
December 25, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…